Effectiveness of Sulbactam/Durlobactam in carbapenem-resistant Acinetobacter baumannii pulmonary infection complicated with carbapenem-resistant Enterobacterales and/or carbapenem-resistant Pseudomonas aeruginosa infection: A prospective, multicenter, cohort study.

Compared to the best available therapy, Sulbactam/Durlobactam plus carbapenems showed a trend toward improved 7-day microbiological clearance (62.5% (10/16) vs. 16.1% (5/31), Cohen's h = 0.998, 0.983 CI [0.261, 1.735]) in carbapenem-resistant Acinetobacter baumannii pulmonary infection co-infected with carbapenem-resistant Enterobacterales (CRE) and/or carbapenem-resistant Pseudomonas aeruginosa (CRPA), yet no significant differences were observed in 14-day, end of treatment, or test of cure microbiological clearance and clinical cure rates, or in intensive care unit and 28-day mortality. Subgroup analysis demonstrated more improvements for patients co-infected with CRE than with CRPA.